Thank you for presenting at the 2025 University at Buffalo Undergraduate Research Conference! As you prepare for your presentation, please review the following important details.

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the 'Company” or 'BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active ...

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX-801 confers durable protection after a single dose TNX-801 is well ...

ZEGFROVY is the onlyapprovedtargeted oral treatmentforNSCLCwith EGFR exon20ins Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part Bstudy, in which ...

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Dizal's ZEGFROVY ...

Presentation Details Title: Phase 1/2 clinical investigation of Invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD (L)1-resistant, ...